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implications for oral nanomedicines
Vishnaka Muraleetharan, Julia Mantaj, Magda Swedrowska and Driton Vllasaliu *
Nanomedicine has shown potential in enabling oral administration of poorly absorbable drugs, such as
biologics. As part of the process related to optimisation of the safety and efficacy of nanomedicines, it is
imperative that the interaction of nanoparticles with the biological systems – including the gut – is fully
characterised. In this article, we provide an overview of the major mechanisms by which nanoparticles
may transform upon introduction in biological media. Specifically, the phenomena of association,
dissolution and biomolecule adsorption are discussed, together with factors which influence the
occurrence of each phenomenon. The implications of these phenomena within the context of
therapeutic action of nanomedicines, which includes reduced targeting efficiency, are also explored.
Finally, we will comment on nanoparticle modification within the gut environment, including the
currently available gastrointestinal models for the study of nano-bio interactions, with implications in the
area of nanomedicines for oral administration.1. Introduction
The oral route of drug administration is favoured due to
convenient administration (ingestion), which facilitates patient
adherence to therapy. However, many drugs, including almost
all biologics – the use of which has proliferated in recent years –
are predominantly delivered via parenteral formulations
because of poor oral bioavailability.1 This can be attributable to
a number of factors, including drug degradation in the gastro-
intestinal (GI) tract and poor intestinal absorption.2 A number
of drug delivery approaches are being researched to improve
oral bioavailability of drugs such as biologics and poorly soluble
drugs. One such approach makes use of drug carriers of nano-
scale dimensions, i.e. nanomedicine. These nanosystems are
usually based on polymeric nanoparticles that are designed to
permeate the intestinal epithelium by targeting epithelial
receptors which transport cargo from the luminal side to the
basolateral (blood) side.3,4 Targeting of biological transport is
thought to be essential as most particulates themselves show
poor permeability across the GI mucosa.5
Nanoparticle biocorona formation, which arises as a result of
interaction of nanoparticles with a range of biomolecules
present in biological milieus (e.g. proteins, lipids, nucleic acids,
metabolites), is a critical phenomenon that determines the
biological fate (therapeutic activity or toxicity) of nanoparticles.
The importance of the biomolecular corona formed around
nanoparticles in biouids in determining bioactivity (particle–of Cancer and Pharmaceutical Science,
t, London, SE1 9NH, UK. E-mail: Driton.
f Chemistry 2019cell interaction) has been demonstrated, for example following
nanoparticle interaction with human plasma (as will be dis-
cussed later). However, characterisation of the biomolecular
corona of nanoparticles in the gastrointestinal biouids
remains poorly understood.6 This knowledge is crucial since
biouid in the GI environments is complex and is likely to
signicantly alter the properties and colloidal stability of
nanoparticles, and thus also their bioavailability and the bio-
logical responses they induce.7 The issue of nanoparticle
modication in the gut and resulting implications for orally
administered nanomedicines has been highlighted in a recent
editorial by Berardi and Bombelli.6 This article aims to further
increase the awareness of this (somewhat understudied) issue
by providing a broader overview and discussion of nanoparticle
behaviour in biological media and a focus on nanoparticle
behaviours in the GI environment and consequences for oral
nanomedicines.
2. The fate of nanoparticles in
biological media and physiological
implications
There are multiple mechanisms by which nanoparticles reduce
their excess surface energy (to attain a more energetically stable
state) on introduction to complex biological media.8 Following
the classical Derjaguin–Landau–Verwey–Overbeek (DLVO)
theory, nanoparticles may cluster into irregularly-shaped larger
entities, namely so agglomerates or dense aggregates.9 Alter-
natively, nanoparticles may dissolve, following the Noyes–
Whitney relationships.10 Nanoparticles can additionally gain
a corona of variable thickness around them, either by adsorbingRSC Adv., 2019, 9, 40487–40497 | 40487
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View Article Onlinebiomolecules from the surroundings or by reacting with the
surroundings (e.g. oxidation), which changes their initial
identity.9,112.1. Association
The long-range thermodynamic forces between colloidal nano-
particles, governed by Brownian motion, result in interparticle
collisions. As per the DLVO theory, nanoparticles may either
associate (ir)reversibly or repel upon such contact, depending
on their short-range thermodynamic interactions. Surface
interactions are simplied by the theory, and the two forces
considered to dominate short-range interparticle interactions
are attractive van der Waal's (vdW) forces and repulsive elec-
trostatic double layer (EDL) forces. Thus, the likelihood of
nanoparticle association is approximately equal to the
summation of these forces, which yields either a net attractive
or net repulsive.
The colloidal stability of nanoparticles is inuenced by both
their inherent properties (e.g. shape, size and surface charge)
and those of the medium in which they are suspended (e.g. pH
and ionic strength). To exemplify, the larger a nanoparticle's net
surface charge, the greater its colloidal stability. For nano-
particles bearing an amphoteric surface (e.g.metal hydroxides),
surface charge is instead a function of the medium's pH. Under
pH values close to their isoelectric point or point of zero charge,
nanoparticles will have a near-neutral net surface charge.
Interparticle repulsions due to the EDL will consequently be
reduced, enhancing the effect of vdW attraction and encour-
aging nanoparticle association.12 Likewise, when subjected to
low ionic strengths, a nanoparticle's EDL extends far from its
surface, causing interparticle repulsions. Conversely, under
high ionic strengths (as is oen present in biouids), the EDL
experiences compression and neutralisation, causing nano-
particle association via a strengthened vdW force.11 By posing
steric repulsion forces, surface coatings of synthetic polymer,
polyelectrolytes or natural organic matter (NOM) may increase
the colloidal stability of nanoparticles. Hydrophilic polymers,
including polyethylene glycol (PEG) and polyvinylpyrrolidone
(PVP), may enable further stabilisation via repulsive short-range
hydration force.12,13
The association of nanoparticles in aqueous biological
media, including cell culture media, may hinder their cellular
targeting efficiency and reduce the representativity of experi-
mental ndings. Moreover, depending on their physicochem-
ical properties and the cell type, nanoparticle association may
skew their cellular uptake and toxicity proles. For example,
aggregated transferrin-capped gold nanoparticles experienced
25% reduced uptake by A549 and HeLa cells compared to their
single, monodispersed counterparts. However, the largest
aggregates underwent two-fold greater uptake by MDA-MB 435
cells. Nevertheless, no unique toxic responses were observed
with the aggregation state.14
Conversely, Zook et al. identied a substantial decrease in
hemolytic toxicity with an increase in size of silver nanoparticle
agglomerates (from 43 nm to 1400 nm).15 Similarly, Tripathy
et al. reported that, compared to small aggregates, large40488 | RSC Adv., 2019, 9, 40487–40497aggregates of zinc oxide nanoparticles exhibit drastically
reduced potency with regards to evoking mitochondrial
dysfunction, producing reactive oxygen species (ROS) and
causing cellular apoptosis in RAW 264.7 murine macrophages.
Interestingly, concentration-dependent aggregation was also
identied here, wherein only small aggregates were formed at
low concentrations of zinc oxide nanoparticles in phosphate
buffer solution (PBS).16
Readers should note that although the association of pris-
tine nanoparticles is possible in biomolecule-free media (in
vitro), once in complex biological uids, the adhesion of
biomolecules on nanoparticles would change the surface char-
acteristics of the latter. As a consequence of the new identity,
nanoparticles could aggregate,17 or on the contrary, in some
cases become more stable.182.2. Dissolution
Nanoparticle dissolution involves the movement of constituent
molecules of a dissolving solid from its surface to the bulk
solution, via a diffusion layer densely occupied by solvated
entities, e.g. biomolecules, solute molecules and ions. Accord-
ingly, the material's solubility in the medium and the surface-
bulk concentration gradient are considered the major driving
forces for this dynamic mechanism. As supported by the Noyes–
Whitney equations, nanoparticles exhibit enhanced dissolution
kinetics compared to bulk materials due to an immense
surface-area-to-volume ratio, a reduced diffusion layer thick-
ness and partially coordinated surface-residing atoms.
Furthermore, with a greater proportion of these surface-
residing atoms at edges and corners compared to at planar
regions, ions and small clusters part from the surface more
easily. Since dissolution can determine in vivo nanoparticle
persistence, it should be considered upon the interpretation of
their biological responses and toxicological proles.10,19,20
Similar to nanoparticle association, dissolution is inuenced
by several factors, both intrinsic and extrinsic. Nanoparticles
oen demonstrate a kinetic size effect wherein the maximum
concentration of dissolved species is observed instantaneously,
aer which the concentration decreases until saturation is
attained. As identied by Schmidt and Vogelsberger for tita-
nium dioxide nanoparticles, this phenomenon is most evident
at larger nanoparticle concentrations.21 An enhanced kinetic
size effect is generally associated with smaller nanoparticle
sizes. For example, there is sufficient evidence in the literature
illustrating an increase in the cytotoxicity of copper oxide when
going from bulk/microscale material to smaller nanoparticles,
by reason of increased solubility.22,23 Similarly, accelerated silver
ion-release with a reduction in particle size, going from
macroscale silver foil to nanoparticles of diameter 60 nm and
4.8 nm, has been reported.24 Conversely, no signicant differ-
ence was observed between the dissolution rates of bulk and
nanoparticulate zinc oxide in Osterhout's medium or
a synthetic freshwater algal medium.23,25
In compliance with the Gibbs–Thomson effect, the dissolu-
tion tendency and equilibrium solubility of particles and
surface structures increase with a reduced radius of positiveThis journal is © The Royal Society of Chemistry 2019
Fig. 1 A simplistic representation showing the factors that can affect
dissolution of nanoparticles and the possible interconnectivity among
the factors, themselves. This figure has been reproduced from ref. 28
with permission from Elsevier.
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View Article Onlinecurvature (i.e. convex); this is due to their energetic instability.
In some instances, their equilibrium solubility may even
surpass their saturation concentration, resulting in precipita-
tion and/or Ostwald ripening. It can thus be deduced that
nanoparticles bearing a reduced radius of negative curvature
(i.e. concave) demonstrate better colloidal stability.10
As discussed above, the colloidal stability of nanostructures
is oen enhanced by the hindrance of interparticle association
through surface coatings. However, the ligands of such stabil-
ising agents may instead alter the dissolution kinetics of the
nanoparticles they harbour.19 For instance, in water at 25 C,
PVP-stabilised silver nanoparticles have demonstrated a greater
degree and rate of dissolution compared to citrate-stabilised
silver nanoparticles. It was postulated that this was because
the citrate layer served as a chemical barrier by reducing the
departing silver ions.26 Contrastingly, Huynh and Chen
observed that, over a 30 min duration in water, citrate-stabilised
silver nanoparticles experienced greater dissolution than PVP-
stabilised silver nanoparticles.27
As well as nanoparticle properties, the nature of the medium
(e.g. pH and ionic strength) may inuence nanoparticle disso-
lution through its effects on the above mentioned phenom-
enon, agglomeration and aggregation.28 The association of
individual nanoparticles reduces their exposed surface area,
thereby hindering ion release to the bulk medium and lowering
the degree of dissolution. Additionally, the association of
nanostructures reduces the number of surface sites which may
be oxidised.29 For instance, the association of goethite nanorods
at reduced pH values and/or increased ionic strengths was
observed to quench, either largely or completely, their
dissolution.30
Changes in the saturation concentration and dissolution
kinetics of nanoparticles due to the availability of organic (e.g.
NOM and polysaccharides) and/or inorganic (e.g. simulated
biouid and buffer) entities, are also documented in the liter-
ature. Dissolution is reportedly ‘catalysed’ by ionic and organic
species capable of forming soluble complexes with the released
ions. Conversely, the generation of less soluble complexes
impedes dissolution.10 For instance, copper oxide nanoparticles
have demonstrated near-complete dissolution in the presence
of tryptone and yeast extract, which are rich in amino acids.
However, no signicant difference in dissolution was measured
upon their exposure to sodium chloride.22 For silver nano-
particles, the addition of a small amount of chloride has been
associated with a signicant reduction in the rate of release of
soluble species.31 Contrastingly, cysteine is reported to enhance
the dissolution of silver nanoparticles.32
The complex relationship between nanoparticle dissolution
and the various intrinsic (e.g. nanoparticle composition, shape,
surface area, surface chemistry, etc.) and extrinsic factors (e.g.
media) is depicted in Fig. 1. Understanding these factors,
facilitates the understanding and prediction of the fate and
biological response of nanoparticles.
The immense contribution of dissolution to the cytotoxicity
of nanoparticles comprising toxic constituent ions (e.g. zinc
oxide), in comparison to that of nanoparticles which are
themselves toxic (e.g. cerium dioxide), has been described in theThis journal is © The Royal Society of Chemistry 2019literature.33 To exemplify, divalent and trivalent cations of
copper and iron (respectively) may evoke site-specic DNA
damage.34 Also, exposure to hexavalent and divalent cations of
chromium and cadmium (respectively) has been shown to
enhance hepatic lipid peroxidation.35 A greater proportion of
copper nanoparticles (relative to copper carbonate salt) were
reported to experience intestinal absorption, accumulate in the
brain tissue and, at greater dietary doses, lead to hepatic
damage in rat models.36 Furthermore, divalent silver and zinc
cations are known to damage the bacterial membrane, thereby
causing bacterial death.37
The employment of nanostructures (which may be consid-
ered a reservoir of cations) for medical applications therefore
necessitates careful consideration. The extent of both the
bactericidal and hemolytic activity of silver nanoparticles has
correlated with the quantity of silver ions released.15,38 Likewise,
oxidative stress and cytotoxicity by cadmium-containing
quantum dots have been associated directly with the intracel-
lular release of constituent divalent cadmium cations.39
However, while enhanced dissolution kinetics of nanoparticles
has been employed in the case of drug nanocrystals to improve
drug dissolution, oral nanomedicines are generally based on
insoluble nanoparticulate carriers, designed to retain the drug
until it reaches the target.2.3. Biomolecule adsorption
On exposure to physiological milieus, nanoparticles may
interact with a range of biomolecules including lipids, nucleic
acids and metabolites. The adsorption of proteins to nano-
particle surface establish a protein corona has been given
particular attention in the recent years, particularly within the
context of nanomedicine targeting. Since many proteins are
amphipathic, they have the potential to interact with almost any
nanoparticle surface in their vicinity. Consequently, the inter-
facial interactions of nanoparticles with proteins are inevitableRSC Adv., 2019, 9, 40487–40497 | 40489
RSC Advances Review
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
6 
D
ec
em
be
r 2
01
9.
 D
ow
nl
oa
de
d 
on
 1
2/
19
/2
01
9 
4:
57
:5
6 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinein such environments. In concordance, as expressed thermo-
dynamically by DadsG < 0 (where DadsG symbolises the Gibbs
free energy of adsorption), this mechanism of lowering the
excess surface energy of nanoparticles is spontaneous.40
The surface adsorption of serum proteins by particles
(opsonisation) was rst postulated by Wright and Douglas in
1903.41 Later in 1962, whilst assessing the surface adsorption of
brinogen in blood plasma, Vroman noticed that the maximum
surface concentration of brinogen was attained at an inter-
mediate time point, suggestive of its substitution by other
proteins with time.42 Described by the Vroman effect, corona
formation is a dynamic and competitive process. The initial
stages of adsorption are dominated by small (high mobility),
abundant proteins. However, with time, some of these proteins
are substituted by those which are larger (low mobility), less
abundant and have greater affinity for the surface.43 An equi-
librium is gradually attained, aer which each protein has equal
rates of association and dissociation, and further exchange
causes no change in the corona's composition.44 As illustrated
in Fig. 2, the protein corona branches into a ‘hard corona’ and
‘so corona’; these denote a rmly bound, equilibrium state
layer (wherein proteins exhibit high affinity for the nanoparticle
surface), and a loosely bound layer (comprised of low-affinity
proteins in rapid exchange with those in the medium),
respectively.45,46
An intrinsic inuencer of protein corona composition is
nanoparticle size. For both citrate-stabilised and PVP-stabilised
silver nanoparticles, proteomic analysis of the acquired corona
revealed that 110 nm nanoparticles associated with almost 1.8
times more serum proteins than did 20 nm nanoparticles.47 TheFig. 2 A schematic representation of the protein corona (PC) which b
proteins which establish the hard corona exhibit higher affinity for the n
slower exchange rate with proteins in the bulk medium than do proteins o
order of hours as oppose to minutes). Hard corona proteins, of which the
soft corona proteins. This figure has been reproduced from ref. 11 with
40490 | RSC Adv., 2019, 9, 40487–40497increased curvature of the smaller nanoparticles likely sup-
pressed the adsorption of proteins, particularly those more
bulky and rigid.48 Contrastingly, due to a size much smaller and
bigger (respectively) than the most abundant serum proteins,
neither 4 nm nor 40 nm gold nanoparticles acquired a complete
protein corona.49 Concordantly, 30 nm gold nanoparticles were
reported to adsorb 2.3 times more plasma proteins than 50 nm
gold nanoparticles.50 This discrepancy suggests the effect of
nanoparticle composition. Concerning protein conformation
within the corona, 6 nm silica nanoparticles evoked a six-fold
reduced modication in the secondary structure of human
carbonic anhydrase 1 than did 15 nm silica nanoparticles.51
Similarly, increasing the size of silica nanoparticles from 4 nm
to 15 nm substantially decreased the stability of adsorbed
ribonuclease A due to increased protein unfolding.52
The association of nanoparticles in solution is known to
both lower their exposed surface area for protein adsorption
(which reduces the density of the corona) and induce surface
rugosity (which evokes conformational changes in the adsorbed
proteins).53 Regarding nanoparticle morphology, gold nanorods
have been observed to undergo greater protein adsorption than
gold nanospheres of equivalent size.54 Likewise, neutral nano-
particles have been reported to bind fewer proteins than their
charged counterparts.55 Between positively-charged and
negatively-charged nanoparticles, the former adsorb the great-
est number of proteins.56 Moreover, employing gold nano-
particles bearing self-assembled monolayers of functionalised
alkyl chains, it was proved that increasing surface hydropho-
bicity increases the corona's density. This is since protein
adsorption is mediated (in part) by hydrophobic interactions.57ranches into two layers, namely the hard and soft coronas. As listed,
anoparticle surface and thus have a longer surface residence time and
f the soft corona (as represented by a smaller rate constant (K off) in the
re are more, also experience greater conformational changes than do
permission from Future Medicine.
This journal is © The Royal Society of Chemistry 2019
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View Article OnlineAs demonstrated by Maiorano et al. utilising Dulbecco's
Modied Eagle medium (DMEM) and Roswell Park Memorial
Institute medium (RPMI), supplemented with Fetal Bovine
Serum (FBS), biouid composition is a prominent extrinsic
inuencer of corona formation. The two media (which vary in
their salt, glucose and amino acid content) induced dissimilar
adsorption patterns, with citrate-stabilised gold nanoparticles
gaining a more abundant and stable corona in DMEM at all
tested sizes.58 Consistently, an increase in plasma concentration
(from 3% to 80%) corresponded to a notable increase in protein
adsorption for polystyrene nanoparticles. For silica nano-
particles, increasing plasma concentration instead induced
considerable changes in the protein pattern, illustrative of
competitive adsorption by less-abundant, high-affinity proteins
due to enhanced adhesion at higher plasma concentrations.59
Finally, nanoparticles which interact with proteins electrostat-
ically have been reported to experience pH-dependent corona
formation by reason of an altered protein binding affinity.60
The instantaneous adsorption of proteins by nanoparticles
may alter their physicochemical attributes (including size and
surface charge), thereby providing them with a new biological
identity. Thus, it is not pristine nanoparticles, but those which
are biomolecule-coated that largely govern physiological
responses such as systemic circulation time, bioavailability,
cellular uptake and cytotoxicity.61 For instance, the formation of
a protein corona around transferrin-functionalised silicon
dioxide nanoparticles was shown to eliminate their transferrin-
mediated targeting capability due to masked receptor-binding
sites (Fig. 3). In another study, the coating of gold nano-
particles with polyacrylic acid was shown to cause the unfolding
of adsorbed brinogen which, consequently, evoked an
inammatory cascade.11
By contrast, serum proteins adsorbed to amine-
functionalised polystyrene nanoparticles were reported to
counterweight the nanoparticle surface charge, be retainedFig. 3 A schematic representation of the loss of transferrin (Tf)-mediated
formation of a protein corona which impedes receptor-binding site inte
from Future Medicine.
This journal is © The Royal Society of Chemistry 2019upon their uptake (by both A549 and 1321N1 cells), and only
experience degradation once trafficked to lysosomes. The har-
bouring of these positively charged nanoparticles averted their
direct encounter with cell membranes, which would have
otherwise induced cell death.62 Similarly, the generation of ROS
(a measure of cytotoxicity) in human acute monocytic
leukaemia (THP-1) cells by cobalt oxide nanoparticles was
observed to be lower following incubation in complete cell
culture medium for 48 h, than in PBS for the same duration.633. Nanoparticle modification in the
gastrointestinal environment
3.1. The changing gastrointestinal environment
3.1.1. Gastrointestinal uid composition. GI uids are
highly complex and heterogeneous, with values of pH and ionic
strength ranging from 1 to 8 and from 10 to >200 mM, respec-
tively, inconsistent viscosity and the presence of various
biomolecules (including bile salts, dietary food and liquid,
digestive enzymes, lipids and lipolysis products). Furthermore,
the GI environment is dynamic, evolving with both internal (e.g.
gastric secretions) and external (e.g. food and/or liquid
consumption) stimuli.6 Inter-subject (albeit more evident in the
postprandial than in the preprandial state) and intra-subject
variability (e.g. from regional specialisation) are also
exhibited.64,65
Luminal uid within the upper small intestine uniquely
comprises chyme from the stomach, as well as secretions from
the following compartments: liver (bile; bicarbonate, bile
pigments, bile salts, cholesterol, phospholipids, and organic
wastes), pancreas (bicarbonate, amylases, lipases and proteases
including trypsin and chymotrypsin) and small intestinal wall
(mineral ions; bicarbonate, chloride and sodium, and water).66
The digestion of silver nanoparticles with food compounds
(carbohydrates, fatty acids and proteins) was reported to havespecificity by Tf-functionalised silicon dioxide nanoparticles due to the
ractions. This figure has been reproduced from ref. 11 with permission
RSC Adv., 2019, 9, 40487–40497 | 40491
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View Article Onlinea negligible impact on nanoparticle uptake by intestinal Caco-2
cells, whilst the digestion of silver nanoparticles in the absence
of food compounds reduced cellular uptake by 60%.67 In
another study, coatings of bovine serum albumin and casein
were found to limit the adhesion of carboxylate-functionalised
polystyrene nanoparticles (of 20 nm, 100 nm and 200 nm
diameter) to Caco-2 cells. Conversely, exposure to meat extract
caused no obvious impact on nanoparticle–cell interaction.
Likewise, incubation in murine intestinal uid increased the
adherence of 20 nm and 100 nm nanoparticles to Caco-2 cells.68
Furthermore, treatment with in vitro digestive solution report-
edly decreased the ROS generation potential of silicon dioxide
and zinc oxide nanoparticles, albeit with no detectable effects
on cytotoxicity.69
In addition to compartmentalisation, the composition of GI
uid is governed by mixing patterns, uid absorption into the
intestinal wall and transit through the intestinal tract. Several
secretions of the small intestine are induced by food
consumption, which gives rise to notable variation in GI uid
composition with prandial state. To exemplify, the consump-
tion of a protein-rich meal (within the usual range of dietary
intake) is followed by a surge in free and peptide amino acids
within the intraluminal contents, originating from the exoge-
neous protein.70 Accordingly, the inuence of protein-, fat- and
carbohydrate-rich meals, as well as high-calorie meals, on drug
absorption have been postulated.71 Thus ultimately, the
prediction of nanoparticle transformation within the GI envi-
ronment necessitates the consideration of regional and pran-
dial effects on GI uid composition, and thereby biomolecule
corona formation.
3.1.2. Changes in mechanical forces and pH. Numerous
contractile motions occur within the bowel wall during normal
gut function, both in the circular and longitudinal muscle
layers. Peristaltic contractions of the circular and longitudinal
muscles demonstrate high synchronisation.72 Within the
stomach, peristaltic forces oen range between 5 and 20
mmHg, however pressures of up to 150 mmHg have been
measured occasionally.73 Ring and segmental contractions of
the small bowel (intestine) serve predominantly to exert
a propulsive force. These follow frequencies of 7 to 20 per
minute, wherein the faster frequencies are characteristic of the
duodenum, and the slower frequencies are found moving
towards the distal ileum.72 However, despite considerable vari-
ability in the strength of such mechanical forces, research
concerning the effect of intestinal contractions on the primary
particle size distribution and aggregation state of nanoparticles
appears to be lacking.73
The preprandial stomach is characterised by acidic pH
values of 1.0 to 2.5, whilst average pH values of 6.6 and 7.5 are
found in the proximal small intestine and terminal ileum,
respectively.74 By contrast, the ingestion of food or liquid may
cause a steep rise in gastric pH, up to values of 6.0 or higher
depending on the composition and volume of the ingested
matter.75 Similarly, the pH of the gastric mucus layer increases
from approximately 1.0 in the lumen, to near-neutral values at
the epithelial cell surface.76 A rise in pH towards the point-of-
zero-charge of titanium dioxide nanoparticles has shown to40492 | RSC Adv., 2019, 9, 40487–40497increase the diameter and decrease the mobility of nanoparticle
aggregates. As supported by the DLVO theory, this is due to the
suppression of their surface ionisation which weakens inter-
particle EDL repulsions, thereby promoting nanoparticle
aggregation.77,78 Thus, the inconsistency of GI pH must also be
considered as a potential inuencer of the therapeutic efficacy
of nanoparticles and nano-scale drug delivery systems, through
its modication of nanoparticle surface properties.3.2. Gastrointestinal models for the study of nanoparticle
behaviour
Major impediments to the characterisation of interactions
between nanoparticles and the biological environment within
the gut, which may explain the knowledge gap in this area to
date, stem from the unavailability of reliable models of the GIT,
in addition to analytical difficulties presented by the complex
mixture of biomolecules (e.g. lipids, proteins and surfactants)
within GI uids. In vivo studies obviously enable a more reliable
evaluation of nanomedicines, including establishing their
toxicological prole, therapeutic response, drug–drug and
drug–food interactions (and subsequent adverse effects), which
are otherwise unidentiable in vitro.79 However, it is imperative
to select an animal model which best simulates the relevant
human system. For example, rats are commonly employed to
predict the human intestinal permeation of conventional
chemicals. However, as a prerequisite, they must undergo
surgery and anaesthesia, which may cause abnormal GI transit
times. As a result of ethical considerations, costs, and inter-
species variability, there is considerable interest in using
representative in vitromodels of the GI biouids and GIT tissue
for the study of nanoparticle behaviour post-ingestion/
administration.
3.2.1. Simulated intestinal uids (biorelevant media). Oral
nanomedicines for systemic effect are assumed to be adminis-
tered via a suitable oral dosage form (e.g. enteric capsule) that
remains intact in the stomach and releases its content in the
small intestine as the primary GI region for absorption. Human
intestinal uids (HIF) may be considered the ‘gold standard’ for
the comprehension of nanoparticle behaviour following oral
administration. Despite this, considerable research has been
dedicated to the development of representative conditions
(including pH, osmolality and composition). Concordantly,
existing studies concerning the GI environment have predom-
inantly utilised simulated intestinal uids (SIF). This is because
the isolation of HIF in volumes large enough for meaningful
drug development studies is unfeasible. The composition of
HIF is also variable, with the donor's prandial state (as
mentioned previously) and the extraction procedure being
major inuencers.80 For a review on intestinal physiology,
including gastrointestinal uid, within the context of drug
delivery, the reader is directed elsewhere.81
Fasted and fed state SIF (FaSSIF-V2 and FeSSIF-V2, respec-
tively) are highly simplistic models of intraluminal composi-
tion. As such, they are deprived of vital intraluminal
components which may render in vitro ndings unreliable. For
example, whilst HIF harbour a variety of bile salts, FaSSIF-V2This journal is © The Royal Society of Chemistry 2019
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View Article Onlineand FeSSIF-V2 comprise pure sodium taurocholate only.82
FeSSIF-V2 additionally fails to replicate the intricate ultra-
structure of postprandial HIF (which includes mixed micelles
and vesicles), likely due to the absence of lipids and lipolysis
products. Furthermore, the movement and enzymatic degra-
dation of food (which impact colloid formation) within the GIT
are unaccounted for.64,83
The addition of pancreatin (and calcium chloride) is one
approach to improve the complexity of FeSSIF-V2.84 The
substitution of sodium taurocholate with crude bile salt extracts
(in both FaSSIF-V2 and FeSSIF-V2) has also proven to better
predict in vivo conditions. However, to ensure the reproduc-
ibility of experimental results, it is oen necessary to stan-
dardise the quantity of bile salt added to crude extract batches.85
3.2.2. In vitro cell models. Cell culture models enable the
high-throughput and reproducible screening of mechanisms by
which chemicals and nanomedicines may undergo trans-
epithelial permeation. Nonetheless, whilst primary epithelial
cells (extracted freshly from the GIT) may be considered the
ideal system, their employment is limited by their short lifespan
in culture and poor ability to form organised monolayers.
Accordingly, in vitro studies on the intestinal absorption of
chemicals and nanomedicines generally utilise immortalised
cell lines which can yield adherent and GIT-representative
monolayers.86 Various cell lines (each reecting a different
region of the GIT) are available, amongst which the intestinal
Caco-2 cell line is highly popular. This is because Caco-2 cells
model enterocytes as the most abundant small intestinal
epithelial cell type.87 Also, when grown to conuence on semi-
permeable inserts, Caco-2 cells differentiate spontaneously
into a polarised monolayer bearing apical brush border
microvilli, intercellular tight junctions and a variety of bio-
relevant metabolic enzymes.88 The Caco-2 model has been
employed widely for the study or nanomedicines for oral
delivery.3,89,90
However, the Caco-2 transwell system accounts for neither
the constant uid ow nor the uid shear stress tolerated by
epithelial cells in vivo, thereby skewing the predicted bioavail-
ability of chemicals and/or nanomedicines.91,92 Caco-2 cell
monolayers additionally lack a mucus coating, which serves to
(i) control the intestinal absorption of matter and (ii) shield the
epithelium from harmful intraluminal contents in vivo.89
Expanding on the latter, bile salts are considerably toxic (irri-
tant) to epithelial cells despite being a major constituent of
intestinal media. Thus, the potentially detrimental impact of
SIF on the Caco-2 intestinal barrier model (whichmay otherwise
be a useful strategy to model both the intestinal luminal uid
and epithelium) may cause the overestimation of trans-
epithelial permeation.93 One strategy to omit this is to instead
employ co-culture models (i.e. Caco-2 cells with mucus-
secreting HT29-MTX cells).94
3.2.3. Dynamic gastric model. Originally developed by the
Institute of Food Research (Norwich; UK), the dynamic gastric
model (DGM) aims to simulate the intricate physical mixing
and emptying conditions of the human gastric system. By
means of a xed outer cylinder and mobile inner cylinder
(between which foods are mechanically crushed), the effect ofThis journal is © The Royal Society of Chemistry 2019various food matrices on the in vivo processing of ingested
nanoparticles (e.g. protein corona composition) may be
assessed. However, the type and strength of the forces applied
by the DGM oen differ from those encountered during peri-
staltic contractions. Furthermore, DGM lacks the representa-
tion of biological components of the GIT (e.g. mucus/mucins),
which may play a crucial role in nanoparticle transformation.
Nevertheless, DGM may have a role in the study of nano-
medicines for oral delivery although further research concern-
ing the biorelevance of DGM-based protocols for the
pharmaceutical assessment of these systems is required.92,95
4. Conclusions
Nanoscale drug delivery systems have been proposed and are
being developed to improve oral drug bioavailability. However,
detailed characterisation of the interactions between these
nanosystems and the biological environment within the gut is
currently lacking, with existing literature on the interactions
and behaviour changes of nanoparticles in physiological envi-
ronments focusing on the blood. Only limited studies have
assessed the modication of nanoparticles on exposure to the
GI tract conditions (e.g. digestion) and these point to signicant
modication of nanosystems in the GI environment, impacting
their bioactivity (including cell uptake and toxicity). More
research is needed in this area, particularly considering the
complexity of the GI tract and the different factors that could
inuence nanoparticle behaviour, including the changing
gastrointestinal uid composition and mechanical forces.
Importantly, study of nanoparticle behaviours in the GI envi-
ronment has to precede and inform research into the design
and development of oral nanomedicines. Otherwise, current
studies focusing on formulation of nanoparticles for oral
delivery, particularly those conducted in vitro and utilising
simple and non-representative models (e.g. media), may be of
limited value.
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